Major clinical overlap of the new and former definition of steatotic liver disease in Germany – evidence from the Wuerzburg Fatty Liver Cohort

Keywords

MASLD - NAFDL - metabolic risk factors - liver stiffness

Schlüsselwörter

MASDL - NAFDL - metabolische Risikofaktoren - Leebersteifigkeit

Publikationsverlauf

Eingereicht: 22. Mai 2024

Angenommen nach Revision: 23. Juni 2024

Artikel online veröffentlicht:
13. Mai 2025

• References

• 1 Geier A, Tiniakos D, Denk H. et al. From the origin of NASH to the future of metabolic fatty liver disease. Gut 2021; 70: 1570-1579
• 2 Rinella ME, Lazarus JV, Ratziu V. et al. NAFLD Nomenclature consensus group. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023; S0168–8278(23)00418-X
• 3 Roeb E, Canbay A, Bantel H. et al. Collaborators: Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – April 2022 – AWMF-Registernummer: 021–025. Z Gastroenterol 2022; 60: 1346-1421
• 4 Lee BP, Dodge JL, Terrault NA. National prevalence estimates for steatotic liver disease and Sub-Classifications using consensus nomenclature. Hepatology 2024; 79: 666-673
• 5 Hagström H, Vessby J, Ekstedt M. et al. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J Hepatol 2024; 80: e76-e77